Meds A-Z
Ceftiofur Crystalline Free Acid
Detailed information about Ceftiofur Crystalline Free Acid
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni in beef, non-lactating dairy, and lactating dairy ca...
What it does:
For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni in beef, non-lactating dairy, and lactating dairy ca...
When it's needed:
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Call your vet sooner if you notice:
- Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Ceftiofur Crystalline Free Acid
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141209 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141235 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- High: Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 1 | |
| 2 | Cat, Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Dog | 1 |
Species coverage: Cat (21) Dog (11)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2023-US-027209
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 9 • Secondary summaries: 0
- UCM307680.pdf · FOI
- UCM203951.pdf · FOI
- ucm117772.pdf · FOI
- ucm117768.pdf · FOI
- ucm117761.pdf · FOI
- EXCEDE® · SPL
- UCM235349.pdf · FOI
- ucm118047.pdf · FOI
- EXCEDE® FOR SWINE · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/733 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/732 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/731 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/730 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/729 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/459/EXCEDE%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/777 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/776 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/282/EXCEDE%C2%AE%20FOR%20SWINE · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:14 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
ucm118047.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141235
-
UCM235349.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141235
-
ucm117761.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141209
-
ucm117768.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141209
-
ucm117772.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141209
-
UCM203951.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141209
-
UCM307680.pdf
• FOI summary • Official
• Feb. 28, 2024
FDA FOI summary for application 141209
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Blindness, Bloody diarrhoea, Corneal disor… (Official, 2026-02-12)
- usage: For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica , Pasteurella multocida , and Histophil… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
EXCEDE®
RX
Ceftiofur Crystalline Free Acid
Sterile suspension
• Subcutaneous, Intramuscular
|
Zoetis Inc. | NADA 141-209 | Approved | Feb 28, 2024 |
|
EXCEDE® FOR SWINE
RX
Ceftiofur Crystalline Free Acid
Sterile suspension
• Intramuscular
|
Zoetis Inc. | NADA 141-235 | Approved | Feb 28, 2024 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle.
Administer as a single subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) to cattle at a dosage of 3.0 mg ceftiofur equivalents (CE)/lb (6.6 mg CE/kg) body weight (BW). In beef and non-lactating dairy cattle, EXCEDE Sterile Suspension may also be administered as a single subcutaneous injection in the middle third of the posterior aspect of the ear at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW.
For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.
Administer as a single subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) to cattle at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW. In beef and non-lactating dairy cattle, may also be administered as a single subcutaneous injection in the middle third of the posterior aspect of the ear at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW.
For the control of respiratory disease in beef and non-lactating dairy catte which are at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.
Administer as a subcutaneous injection either in the middle third of the posterior aspect of the ear or in the posterior aspect of the ear where it attaches to the head (base of the ear) to beef and non-lactating dairy cattle at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW.
For treatment of acute metritis (0-10 days post-partum) associated with bacterial organisms susceptible to ceftiofur in lactating dairy cattle.
Administer as a subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) to lactating dairy cattle at a dosage of 3.0 mg CE/lb (6.6 mg CE/kg) BW. Repeat this dose in the contra-lateral (opposite) ear approximately 72 hours following the initial dose.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis; and for the control of SRD associated with A. pleuropneumoniae, P. multocida, H. parasuis, and S. suis in groups of pigs where SRD has been diagnosed.
Administer by intramuscular (IM) injection in the post-auricular region of the neck as a single dosage of 5.0 mg ceftiofur equivalents (CE)/kg body weight (BW). No more than 2 mL should be injected in a single injection site.
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
FOI UCM307680.pdf
Summary
This supplemental application provides for the addition of a new indication for the treatment of acute metritis (0 to 10 days postpartum) associated with bacterial organisms susceptible to ceftiofur in lactating dairy cattle; and to provide modified injection techniques for the base of the ear route of administration. -
FOI UCM203951.pdf
Summary
This supplement provides for a new indication, for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi ssp. zooepidemicus. -
FOI ucm117772.pdf
Summary
This supplement provides for a new indication, treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle. -
FOI ucm117768.pdf
Summary
1. To add a new route of administration for injection in the posterior aspect of the ear where it attaches to the head (base of ear).
2. To add a new indication, “For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in lactating dairy cattle.”
3. To establish a 13-day pre-slaughter withdrawal period for cattle. -
FOI ucm117761.pdf
Summary
NAXCEL XT STERILE SUSPENSION is indicated for treatment of BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida and H. omnus. NAXCEL XT STERILE SUSPENSION is also indicated for the control of respiratory disease in cattle which are at high risk of developing BRD associated with Mannheimia. haemolytica, P. multocida and H. somnus.
- EXCEDE® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM235349.pdf
Summary
This supplement provides for a new indication for the control of SRD associated with A. pleuropneumoniae, P. multocida, H. parasuis, and S. suis in groups of pigs where SRD has been diagnosed. -
FOI ucm118047.pdf
Summary
For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.
- EXCEDE® FOR SWINE (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle. For the control of respiratory disease in beef and non-lactating dairy catte which are at high risk of developing BRD associated with M. haemolytica , P. multocida , and H. somni .
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 8 and Cat 8 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Retriever - Labrador, Female, 6 year, 29.03 kilogram • Drug: MSK, Suspension, Unknown, Dose: 2 mL per animal • Reactions: Not eating, Lack of efficacy - NOS, Medication error NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-045892
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 6.00 Year
- Weight: 29.030 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Suspension
- Dose: 2 mL per animal
Dog, Brittany, Male, 5 year, 20.638 kilogram • Drug: MSK, Suspension, Unknown • Reactions: Limping, Neuropathy NOS, Muscle inflammation • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-075164
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 5.00 Year
- Weight: 20.638 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Suspension
Cat, Domestic Shorthair, Male, 5 month, 2.268 kilogram • Drug: MSK, Suspension, Unknown • Reactions: Shaking, Nystagmus, Icterus, Polyuria, Unsteady walking (ataxia)… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-003400
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 5.00 Month
- Weight: 2.268 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Suspension
Dog, Deutsche Dogge, Great Dane, Male, 7 year, 65.317 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 2 mL per animal • Reactions: Sedation prolonged, Staggering, Nausea, Panting, Elevated renal parameters… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2024-US-000361
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 7.00 Year
- Weight: 65.317 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 2 mL per animal
Cat, Domestic Shorthair, Male, 16 day, 3.447 kilogram • Drug: MSK, Suspension, Unknown • Reactions: Tiredness (lethargy), Vomiting, Diarrhea, Fracture, Anaemia NOS… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2023-US-027209
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 16.00 Day
- Weight: 3.447 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Suspension
Cat, Cat (other), Unknown • Drug: MSK, Suspension, Subcutaneous • Reactions: Eye haemorrhage, Pinnal haemorrhage, Injection site swelling, Stiffness limb, Loss of appetite… • Outcome: Died
- Report ID: USA-USFDACVM-2023-US-013044
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Unknown
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
Cat, Domestic Longhair, Male, 4.536 kilogram • Drug: MSK, Suspension, Unknown • Reactions: Laboured breathing, Hiding • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2020-US-060698
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Weight: 4.536 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Suspension
Cat, Domestic Longhair, Female, 2.722 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1 mL per animal • Reactions: Fever, Dehydration, Weight loss, Elevated creatinine • Outcome: Ongoing
- Report ID: USA-USFDACVM-2020-US-033939
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Weight: 2.722 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 1 mL per animal
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.